22236-1-AP
antibody from Proteintech Group
Targeting: BRD2
BRD2-IT1, D6S113E, FSRG1, KIAA9001, NAT, RING3
Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 22236-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#22236-1-AP, RRID:AB_2722524
- Product name
- BRD2 antibody
- Antibody type
- Polyclonal
- Description
- BRD2 antibody (Cat. #22236-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IP, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.
The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Wang W, Tang YA, Xiao Q, Lee WC, Cheng B, Niu Z, Oguz G, Feng M, Lee PL, Li B, Yang ZH, Chen YF, Lan P, Wu XJ, Yu Q
Nature communications 2021 Jul 21;12(1):4441
Nature communications 2021 Jul 21;12(1):4441
The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.
Bian X, Wang X, Zhang Q, Ma L, Cao G, Xu A, Han J, Huang J, Lin W
Frontiers in oncology 2020;10:565820
Frontiers in oncology 2020;10:565820
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W
Nature medicine 2017 Sep;23(9):1063-1071
Nature medicine 2017 Sep;23(9):1063-1071
No comments: Submit comment
No validations: Submit validation data